Intra-Cellular Therapies, Inc. (ITCI) 은(는) 상장 기업입니다 헬스케어 섹터의 Drug Manufacturers - Specialty & Generic 산업에서 운영. 본사 소재지는 New York City, NY, 미국. 현재 CEO는 Sharon Mates.
ITCI 을(를) 보유 IPO 날짜 2014-01-07, 860 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $14.05B.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company headquartered in New York that develops novel medications for neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms in the central nervous system. The company's approved product CAPLYTA treats schizophrenia in adults, while its clinical pipeline includes lumateperone in Phase III trials for bipolar depression and autism spectrum disorder, Lenrispodun for Parkinson's disease and heart failure, ITI-1284-ODT-SL for dementia-related behavioral disturbances, and ITI-333 for substance use disorders and psychiatric conditions. Founded in 2002, the company focuses on addressing significant unmet medical needs in the neuropsychiatric market through innovative drug development.
